Suppression of APOBEC3-mediated Restriction of HIV-1 by Vif
Overview
Affiliations
The APOBEC3 restriction factors are a family of deoxycytidine deaminases that are able to suppress replication of viruses with a single-stranded DNA intermediate by inducing mutagenesis and functional inactivation of the virus. Of the seven human APOBEC3 enzymes, only APOBEC3-D, -F, -G, and -H appear relevant to restriction of HIV-1 in CD4+ T cells and will be the focus of this review. The restriction of HIV-1 occurs most potently in the absence of HIV-1 Vif that induces polyubiquitination and degradation of APOBEC3 enzymes through the proteasome pathway. To restrict HIV-1, APOBEC3 enzymes must be encapsidated into budding virions. Upon infection of the target cell during reverse transcription of the HIV-1 RNA into (-)DNA, APOBEC3 enzymes deaminate cytosines to form uracils in single-stranded (-)DNA regions. Upon replication of the (-)DNA to (+)DNA, the HIV-1 reverse transcriptase incorporates adenines opposite to the uracils thereby inducing C/G to T/A mutations that can functionally inactivate HIV-1. APOBEC3G is the most studied APOBEC3 enzyme and it is known that Vif attempts to thwart APOBEC3 function not only by inducing its proteasomal degradation but also by several degradation-independent mechanisms, such as inhibiting APOBEC3G virion encapsidation, mRNA translation, and for those APOBEC3G molecules that still become virion encapsidated, Vif can inhibit APOBEC3G mutagenic activity. Although most Vif variants can induce efficient degradation of APOBEC3-D, -F, and -G, there appears to be differential sensitivity to Vif-mediated degradation for APOBEC3H. This review examines APOBEC3-mediated HIV restriction mechanisms, how Vif acts as a substrate receptor for a Cullin5 ubiquitin ligase complex to induce degradation of APOBEC3s, and the determinants and functional consequences of the APOBEC3 and Vif interaction from a biological and biochemical perspective.
APOBEC3-Related Editing and Non-Editing Determinants of HIV-1 and HTLV-1 Restriction.
Leong S, Nasser H, Ikeda T Int J Mol Sci. 2025; 26(4).
PMID: 40004025 PMC: 11855278. DOI: 10.3390/ijms26041561.
Gaba A, Yousefi M, Bhattacharjee S, Chelico L J Virol. 2024; 99(1):e0160624.
PMID: 39714157 PMC: 11784016. DOI: 10.1128/jvi.01606-24.
Mathieu S, Gillet N Mol Ther Oncol. 2024; 32(4):200901.
PMID: 39624056 PMC: 11609522. DOI: 10.1016/j.omton.2024.200901.
Is the Central Nervous System Reservoir a Hurdle for an HIV Cure?.
Mohammadzadeh N, Chomont N, Estaquier J, Cohen E, Power C Viruses. 2023; 15(12).
PMID: 38140626 PMC: 10747469. DOI: 10.3390/v15122385.
Structural insights into RNA bridging between HIV-1 Vif and antiviral factor APOBEC3G.
Kouno T, Shibata S, Shigematsu M, Hyun J, Kim T, Matsuo H Nat Commun. 2023; 14(1):4037.
PMID: 37419875 PMC: 10328928. DOI: 10.1038/s41467-023-39796-5.